Polomar Health Services (PMHS) EBITDA Margin (2022 - 2026)
Polomar Health Services (PMHS) posted EBITDA Margin of 14.29% for Q2 2026, up 2181.13% on a QoQ basis from 0.69% in Q1 2026, and up 1031288.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Polomar Health Services (PMHS) EBITDA Margin (2022 - 2026) Analysis & Trends
Polomar Health Services has reported EBITDA Margin for 5 years, with the latest figure at 14.29% in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 1031288.0% year-over-year to 14.29% in Q2 2026; TTM through Jun 2026 was 295.04%, a 443606.0% increase from a year earlier, with the FY2025 full-year figure at 1627.55%, up 58158.0% from the prior year.
- EBITDA Margin was 14.29% for Q2 2026 at Polomar Health Services, up from 0.69% in the prior quarter.
- The five-year high for EBITDA Margin was 14.29% in Q2 2026, with the low at 10298.59% in Q2 2025.
- Average EBITDA Margin over 5 years is 2961.2%, with a median of 1247.48% recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 898268 bps in 2025, then surged 1031288 bps in 2026.
- Over 5 years, EBITDA Margin stood at 506.59% in 2022, then decreased by 8 bps to 546.84% in 2023, then slumped by 504 bps to 3301.93% in 2024, then jumped by 57 bps to 1414.86% in 2025, then surged by 101 bps to 14.29% in 2026.
- The last three EBITDA Margin figures came in at 14.29% (Q2 2026), 0.69% (Q1 2026), and 1414.86% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 9.72% |
| 10 | Polomar Health Services | 5.66 Mn | 5.48 Mn | 935,916.00 | 14.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.29% |
| Mar 31, 2026 | -0.69% |
| Dec 31, 2025 | -1,414.86% |
| Sep 30, 2025 | -10,202.95% |
| Jun 30, 2025 | -10,298.59% |
| Mar 31, 2025 | -9,145.93% |
| Dec 31, 2024 | -3,301.93% |
| Sep 30, 2024 | -2,631.47% |
| Jun 30, 2024 | -1,315.92% |
| Mar 31, 2024 | -1,179.04% |
| Dec 31, 2023 | -546.84% |
| Sep 30, 2023 | -627.66% |
| Dec 31, 2022 | -506.59% |
| Sep 30, 2022 | -298.67% |